PPARG and malignant colon neoplasm: Previous reports have shown that the PPARγ agonist troglitazone inhibits colon cancer metastasis by inhibiting matrix metalloproteinase-7 (MMP-7) synthesis and the adhesion of extracellular matrix (ECM) proteins [42, 114].